RAPGEF5 and gastrointestinal stromal tumor: Gain-of-function mutations of the GFR KIT or PDGFRα in gastrointestinal stromal tumor (GIST), and the activity of fusion proteins FUS-DDIT3 and PAX3-FOXO1 in myxoid liposarcoma (MLPS) and alveolar rhabdomyosarcoma (ARMS), respectively, enhance IGF1R expression, a major driver of RAS/AKT/mTOR activation, and promote sarcoma progression [36,57].